Serina Therapeutics (NYSEAMERICAN:SER – Get Free Report)‘s stock had its “buy” rating reissued by investment analysts at BTIG Research in a research report issued to clients and investors on Monday, Benzinga reports. They presently have a $8.00 target price on the stock. BTIG Research‘s price target points to a potential upside of 367.84% from the stock’s current price.
Serina Therapeutics Price Performance
NYSEAMERICAN:SER traded up $0.06 during trading hours on Monday, hitting $1.71. The company’s stock had a trading volume of 38,290 shares, compared to its average volume of 1,431,775. The business’s 50-day moving average is $2.24 and its two-hundred day moving average is $2.08. The company has a market capitalization of $43.43 million, a PE ratio of -0.90 and a beta of 1.19. The company has a debt-to-equity ratio of 0.16, a quick ratio of 6.65 and a current ratio of 6.65. Serina Therapeutics has a 52-week low of $1.22 and a 52-week high of $5.25.
Serina Therapeutics (NYSEAMERICAN:SER – Get Free Report) last released its quarterly earnings data on Thursday, August 13th. The company reported ($0.55) earnings per share (EPS) for the quarter.
Serina Therapeutics Company Profile
Serina Therapeutics is a clinical-stage biopharmaceutical company developing medicines designed to provide longer-lasting and more consistent therapeutic effects. The company uses its proprietary POZ polymer technology to modify existing drug compounds, with the goal of extending their duration of action and potentially improving treatment convenience and tolerability.
Serina’s lead program is POZ-apomorphine, also referred to as SER-252, an investigational therapy being developed for patients with advanced Parkinson’s disease.
Read More
- Five stocks we like better than Serina Therapeutics
- Comfort Systems Earnings: AI Slowdown or More Growth Ahead?
- Bristol Myers Squibb’s Cancer Breakthrough Could Have Implications Beyond Its Own Stock
- 5 Beaten-Down Growth Stocks Trading Like Value Plays as Cash Chases Mega-Caps
- Anthropic’s IPO Filing Reveals a Massive Opportunity for AI Infrastructure Giants
Receive News & Ratings for Serina Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Serina Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
